Gossamer Bio Plans to Raise $264.5 Million with IPO

Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas. 

The biopharma company focuses on immunobiology, specifically immunology, inflammation, immuno-oncology and fibrosis. It has four programs, two in Phase II, one in Phase I and a preclinical research program.